Haemonetics Corporation (HAE)
Financial leverage ratio
Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | ||
---|---|---|---|---|---|---|
Total assets | US$ in thousands | 2,450,950 | 2,195,590 | 1,934,820 | 1,859,730 | 1,819,920 |
Total stockholders’ equity | US$ in thousands | 820,836 | 959,959 | 817,997 | 749,424 | 731,670 |
Financial leverage ratio | 2.99 | 2.29 | 2.37 | 2.48 | 2.49 |
March 31, 2025 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $2,450,950K ÷ $820,836K
= 2.99
The financial leverage ratio of Haemonetics Corporation has shown a slight decline over the past few years, from 2.49 in 2021 to 2.29 in 2024. This indicates that the company's reliance on debt to finance its operations has been decreasing. However, it is worth noting that the ratio is not available for 2025, possibly indicating a lack of data for that year. Overall, the decreasing trend in the financial leverage ratio suggests that Haemonetics Corporation is managing its debt levels effectively and becoming less leveraged over time.
Peer comparison
Mar 31, 2025
Company name
Symbol
Financial leverage ratio
Haemonetics Corporation
HAE
2.99
3M Company
MMM
10.38
Artivion Inc
AORT
2.86
Baxter International Inc
BAX
3.70
Becton Dickinson and Company
BDX
2.21
Boston Scientific Corp
BSX
1.81
DexCom Inc
DXCM
3.08
Embecta Corp
EMBC
—
Glaukos Corp
GKOS
1.27
Globus Medical
GMED
1.26
ICU Medical Inc
ICUI
2.14